{
  "metadata": {
    "input_documents": [
      "ar-ra-2022-23-en.pdf",
      "CREST-Annual-Report-2023.pdf",
      "CREST-Annual-Report-2022.pdf",
      "CREST-Annual-Report-2024.pdf",
      "AR2122.pdf",
      "ar-ra-2023-2024-doc-en.pdf",
      "BIOMERIEUX_ANNUAL-REPORT_2024_EN.pdf.coredownload.pdf",
      "bioMérieux-2023-Annual-Report.pdf.coredownload.pdf",
      "Annual_Report_2022_bioMérieux.pdf.coredownload.pdf"
    ],
    "persona": {
      "role": "Investment Analyst",
      "expertise": "Technology and Healthcare Sectors"
    },
    "job_to_be_done": {
      "task": "Analyze revenue trends, R&D investments, and market positioning strategies",
      "focus": [
        "revenue trends",
        "R&D investments",
        "market positioning strategies"
      ]
    },
    "processing_timestamp": "2025-07-28T17:33:30.085522"
  },
  "extracted_sections": [
    {
      "document": "Annual_Report_2022_bioMérieux.pdf.coredownload.pdf",
      "page_number": 13,
      "section_title": "spirit passed down from generation to generation. R&D",
      "importance_rank": 1
    },
    {
      "document": "bioMérieux-2023-Annual-Report.pdf.coredownload.pdf",
      "page_number": 13,
      "section_title": "AT ALL LEVELS OF THE COMPANY BY INVESTING",
      "importance_rank": 2
    },
    {
      "document": "BIOMERIEUX_ANNUAL-REPORT_2024_EN.pdf.coredownload.pdf",
      "page_number": 4,
      "section_title": "What are its priority areas?",
      "importance_rank": 3
    },
    {
      "document": "Annual_Report_2022_bioMérieux.pdf.coredownload.pdf",
      "page_number": 13,
      "section_title": "Strong investments to support the",
      "importance_rank": 4
    },
    {
      "document": "BIOMERIEUX_ANNUAL-REPORT_2024_EN.pdf.coredownload.pdf",
      "page_number": 3,
      "section_title": "P.24",
      "importance_rank": 5
    },
    {
      "document": "BIOMERIEUX_ANNUAL-REPORT_2024_EN.pdf.coredownload.pdf",
      "page_number": 15,
      "section_title": "therefore relies on a strong contribution from Marketing,",
      "importance_rank": 6
    },
    {
      "document": "BIOMERIEUX_ANNUAL-REPORT_2024_EN.pdf.coredownload.pdf",
      "page_number": 10,
      "section_title": "Makes",
      "importance_rank": 7
    },
    {
      "document": "BIOMERIEUX_ANNUAL-REPORT_2024_EN.pdf.coredownload.pdf",
      "page_number": 5,
      "section_title": "Headquarters",
      "importance_rank": 8
    },
    {
      "document": "AR2122.pdf",
      "page_number": 8,
      "section_title": "goals in our 2019-22 Strategic Plan:",
      "importance_rank": 9
    },
    {
      "document": "CREST-Annual-Report-2022.pdf",
      "page_number": 13,
      "section_title": "Access to Cyber",
      "importance_rank": 10
    }
  ],
  "subsection_analysis": [
    {
      "document": "Annual_Report_2022_bioMérieux.pdf.coredownload.pdf",
      "section_title": "spirit passed down from generation to generation. R&D",
      "refined_text": "is an important foundation for our growth and serves\nour long-term vision.\nmedical value of diagnostics and industrial applications: a specific\nlaboratory efficacy approach\nIn the clinical field, R&D works across the In the field of industrial microbiology,\nvalue chain and interacts with all Company bioMérieux invests approximately 8% of its\nfunctions. It helps fuel our strategy and boost sales in R&D, a rate well above the industry\nour activity. The share of sales generated by average.\nnewly launched products has highly increased\nsince 2020. A significant amount of the R&D Augmented diagnostics, a tailored\nbudget is invested in disruptive innovation response for the food and beverage\nto prepare for the future. industry\n",
      "page_number": 13
    },
    {
      "document": "BIOMERIEUX_ANNUAL-REPORT_2024_EN.pdf.coredownload.pdf",
      "section_title": "What are its priority areas?",
      "refined_text": "We have identified four dimensions. +7% organic growth year after year at constant\nexchange rate by 2028, on current business\nThe first dimension relates to the various growth drivers for the coming\nyears. Those that will enable us to provide access to our diagnostic\nsolutions to as many patients and manufacturers as possible.\nThe second dimension relates to the simplification of our operating model. Reach 20% contributive EBIT margin*\nbioMérieux was built on an extraordinarily entrepreneurial model. We now by 2028, at constant exchange rate\nhave 14,600 team members, and we need to remain agile and efficient in\norder to make swift decisions, while remaining as close as possible to the\nhealthcare professionals and manufacturers who place their trust in us.\n",
      "page_number": 4
    }
  ]
}